EU/3/20/2294: Orphan designation for the treatment of idiopathic pulmonary fibrosis

Sodium cromoglicate


On 26 June 2020, orphan designation EU/3/20/2294 was granted by the European Commission to IQVIA RDS Spain S.L., Spain, for sodium cromoglicate for the treatment of idiopathic pulmonary fibrosis.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2020 on request of the Sponsor.

Key facts

Active substance
Sodium cromoglicate
Intended use
Treatment of idiopathic pulmonary fibrosis
Orphan designation status
EU designation number
Date of designation

Calle De Juan Esplandiu 11 Planta 6
28007 Madrid
Tel. +34 918 066340

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating